Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01811212
Show Display Options
Rank Status Study
1 Suspended Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Conditions: Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage I Thyroid Gland Follicular Carcinoma;   Stage I Thyroid Gland Papillary Carcinoma;   Stage II Thyroid Gland Follicular Carcinoma;   Stage II Thyroid Gland Papillary Carcinoma;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Oncocytic Follicular Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years